Collegium Pharmaceutical, Inc. (COLL) Stock Grade

About Collegium Pharmaceutical, Inc.'s fundamentals

Collegium Pharmaceutical demonstrates solid financial performance with revenue growing 23.6% year-over-year and an 8.1% net margin, indicating both expansion and profitability in its specialty drug business. The company generates a strong return on equity of 20.8%, suggesting efficient use of shareholder capital. With a market capitalization of $1.5 billion and a P/E ratio of 23.4, the valuation reflects investor expectations aligned with the company's growth trajectory. The company does not currently pay a dividend, maintaining flexibility to reinvest earnings into its operations.